# Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/SNDX
## Company Profile
- Ticker: SNDX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology, Hematology
## Stock Data
- Close: 19.92 USD
- Market cap: 1629538396.53 USD
- Last updated: 2026-08-05
## Business Overview
### Commercial Oncology Portfolio
Syndax Pharmaceuticals develops and commercializes therapies for genetically defined leukemias and immune-mediated complications of transplantation. Its commercial portfolio is built around Revuforj and Niktimvo.
### Revuforj
Revuforj, or revumenib, is a menin inhibitor used in acute leukemias with susceptible genetic drivers. Ongoing studies evaluate frontline combinations, post-transplant maintenance and additional molecular subgroups, including NPM1-mutant, KMT2A-rearranged and NUP98-rearranged disease.
### Niktimvo
Niktimvo, or axatilimab, targets CSF-1 receptor biology and is commercialized for chronic graft-versus-host disease. Syndax is testing the molecule in newly diagnosed chronic GVHD and idiopathic pulmonary fibrosis to expand beyond its initial indication.
### Frontline Registrational Strategy
Syndax is advancing pivotal trials intended to establish revumenib in frontline acute myeloid leukemia. It also plans the RAVEN study as part of the asset’s broader development program.
## Why The Stock Is Moving

Following the latest company update, “Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update”, SNDX closed up 4.40% at $19.92 on Aug 5, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- New revumenib real-world, frontline and post-transplant maintenance data expected in the second quarter of 2026.
- Additional revumenib data presentations from ongoing studies during the second half of 2026.
- Initiation of the RAVEN trial expected in the second half of 2026.
- Topline Phase 2 data for axatilimab in idiopathic pulmonary fibrosis and newly diagnosed chronic GVHD expected in the fourth quarter of 2026.

## Drug Assets

- Revuforj

## Recent News
- 2026-08-04 20:01 EST — [Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/SNDX/syndax-reports-second-quarter-2026-financial-results-and-provides-business-updat-f0b01267) — Source: Syndax Pharmaceuticals
- 2026-07-28 11:00 EST — [Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026](https://biopharmsignal.com/news/SNDX/syndax-to-announce-second-quarter-2026-financial-results-and-host-conference-cal-ea131128) — Source: Syndax Pharmaceuticals
- 2026-07-14 12:00 EST — [Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event](https://biopharmsignal.com/news/SNDX/syndax-to-highlight-late-stage-programs-and-unveil-new-pipeline-assets-at-r-d-ev-34c76450) — Source: Syndax Pharmaceuticals
- 2026-06-11 11:03 EST — [Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026](https://biopharmsignal.com/news/SNDX/syndax-showcases-revuforj-revumenib-clinical-activity-in-multiple-acute-leukemia-f498202f) — Source: Syndax Pharmaceuticals
- 2026-06-11 11:00 EST — [Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology](https://biopharmsignal.com/news/SNDX/syndax-announces-publication-of-save-data-on-revuforj-revumenib-in-combination-w-271b6070) — Source: Syndax Pharmaceuticals